CN108663448A - Detection method in relation to substance in a kind of Amino Acid Compound Injection - Google Patents

Detection method in relation to substance in a kind of Amino Acid Compound Injection Download PDF

Info

Publication number
CN108663448A
CN108663448A CN201810457668.7A CN201810457668A CN108663448A CN 108663448 A CN108663448 A CN 108663448A CN 201810457668 A CN201810457668 A CN 201810457668A CN 108663448 A CN108663448 A CN 108663448A
Authority
CN
China
Prior art keywords
amino acid
acid compound
solution
compound injection
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201810457668.7A
Other languages
Chinese (zh)
Other versions
CN108663448B (en
Inventor
山广志
左利民
徐士婕
李盼盼
宗艳平
朱志玲
赵婷
朱明慧
孙伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Medicinal Biotechnology of CAMS
Original Assignee
Institute of Medicinal Biotechnology of CAMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Medicinal Biotechnology of CAMS filed Critical Institute of Medicinal Biotechnology of CAMS
Priority to CN201810457668.7A priority Critical patent/CN108663448B/en
Publication of CN108663448A publication Critical patent/CN108663448A/en
Application granted granted Critical
Publication of CN108663448B publication Critical patent/CN108663448B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/04Preparation or injection of sample to be analysed
    • G01N30/06Preparation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/04Preparation or injection of sample to be analysed
    • G01N2030/042Standards

Abstract

The present invention provides the detection method in relation to substance in a kind of Amino Acid Compound Injection, this method is using 5 hydroxytryptophans and L kynurenins as pointer impurity, the various amino acid contained in amino acid injection and the separation in relation to substance and baseline stability are optimized by trifluoroacetic acid hyptafluorobutyric acid Ion-pair chromalography method, detection sensitivity is high, accuracy and favorable reproducibility disclosure satisfy that the requirement of related substance control in Amino Acid Compound Injection.

Description

Detection method in relation to substance in a kind of Amino Acid Compound Injection
Technical field
The present invention relates to related in the detection method in relation to substance, especially Amino Acid Compound Injection in a kind of injection The detection method of substance.
Background technology
Amino acid is the basic unit and body synthetic antibody, hormone, enzyme and its hetero-organization for constituting human body protein Raw material.Amino Acid Compound Injection, which is generally used for the amino acid such as protein insufficiency of intake, malabsorption, cannot meet organism metabolism The patient needed also is used to improve the nutrition condition of patients after surgery.However, the uncharged amino acid injection of pharmacopoeia of each country The related substance detecting method of liquid.Although there is pharmacopeia to record the detection method in relation to substance in amino acid starting material, these are related Substance is remaining process contaminants, mostly Endogenous Amino Acids during amino acids production, by other ammonia in compound preparation prescription Base acid starting material is covered, to cannot be satisfied the requirement of related substance detection in Amino Acid Compound Injection.
Invention content
The present invention provides the detection method in relation to substance in a kind of Amino Acid Compound Injection, this method determines compound Pointer impurity in amino acid injection, detection sensitivity is high, accuracy and favorable reproducibility, disclosure satisfy that amino acid is noted Penetrate the requirement of related substance control in liquid.
The present invention relates to the detection method in relation to substance in a kind of Amino Acid Compound Injection, this method includes following step Suddenly:
(1) preparation of test solution and reference substance solution:
Amino Acid Compound Injection is taken to be directly used as test solution;
Prepare the 5HTP reference substance solution of at least three various concentration and the L- dogs urine of at least three various concentration Propylhomoserin reference substance solution;
(2) it takes the 5HTP reference substance solution of various concentration to inject high performance liquid chromatograph, records 280nm wavelength The chromatogram of the 5HTP reference substance solution of lower various concentration, with a concentration of abscissa of 5HTP, with this Peak area corresponding to concentration is ordinate, makes standard curve or regression equation;The L- kynurenins of various concentration are taken to compare Product solution injects high performance liquid chromatograph, records the chromatography of the L- kynurenin reference substance solutions of various concentration under 365nm wavelength Figure, using the peak area corresponding to the concentration as ordinate, is made standard curve or returned with a concentration of abscissa of L- kynurenins Return equation;
(3) take test solution inject high performance liquid chromatograph, record 280nm wavelength under and 365nm wavelength under test sample The chromatogram of solution, by calibration curve method, with the peak area root of 5HTP in test solution 280nm wavelength chromatograms According to the amount of 5HTP in standard curve or regression equation calculation test solution, Amino Acid Compound Injection must not exceed The 0.2% of middle tryptophan labelled amount, with the peak area of L- kynurenins in test solution 365nm wavelength chromatograms according to standard The amount of L- kynurenins, must not exceed tryptophan in Amino Acid Compound Injection in curve or regression equation calculation test solution The 0.2% of labelled amount;
Wherein, contain tryptophan in the Amino Acid Compound Injection.
The present inventor has found that tryptophan is amino acid most unstable in 20 kinds of amino acid by numerous studies, For the Amino Acid Compound Injection containing tryptophan, 5HTP, L- kynurenins are earliest appearance, generate speed most Impurity fast and that amount is most, to which 5HTP and L- kynurenins are determined as the pointer in Amino Acid Compound Injection Property impurity.
It will be understood by those skilled in the art that the various Amino Acid Compound Injections containing tryptophan can all use the present invention's Method detects related substance therein, including but not limited to:Amino acid (15) double peptides (2) injection, amino acid note Penetrate liquid (18AA) (specification includes 5% and 12%), Amino Acid Compound Injection (18AA-I), Amino Acid Compound Injection (18AA- II) (specification includes 5%, 8.5%, 11.4%), Amino Acid Compound Injection (18AA-III), Amino Acid Compound Injection (18AA-V), Amino Acid Compound Injection (18AA- VII), Amino Acid Compound Injection (20AA), Amino Acid Compound Injection (15AA), Amino Acid Compound Injection (14AA), Amino Acid Compound Injection (17AA) etc., it is preferable that amino acid (15) Double peptide (2) injections.
In one preferred embodiment, in step (1), it is molten further to prepare the control containing test solution Liquid;In step (2), contrast solution is further taken to inject high performance liquid chromatograph, records the color of contrast solution under 280nm wavelength Spectrogram;It is single if detecting other chromatographic peaks in test solution 280nm wavelength chromatograms by Self-control method in step (3) A peak area is by the way that compared with tryptophan peak area in contrast solution, content must not exceed tryptophan in Amino Acid Compound Injection The 0.5% of labelled amount, total peak area is by the way that compared with tryptophan peak area in contrast solution, content must not exceed amino acid The 5% of tryptophan labelled amount in injection.
It will be understood by those skilled in the art that various solvents commonly used in the art can be used to prepare 5HTP pair According to product solution and L- kynurenin reference substance solutions.It is preferred that the solvent of reference substance solution is diluted hydrochloric acid aqueous solution, more preferable concentration For the aqueous hydrochloric acid solution of 0.1mol/L.
It will be understood by those skilled in the art that various solvents commonly used in the art can be used to prepare pair of test solution According to solution.It is preferred that the solvent of contrast solution is diluted hydrochloric acid aqueous solution, the aqueous hydrochloric acid solution of more preferable a concentration of 0.1mol/L.
Preferably, 3-7 are prepared, further preferred 3-5, the 5HTP of more preferable 3 various concentrations compares Product solution.Those skilled in the art have in multiple reference substance solutions that ability is chosen for making standard curve or regression equation The concentration of 5HTP.Preferably, Cmin should be less than tryptophan labelled amount in Amino Acid Compound Injection 0.1%, maximum concentration should be higher than that 0.4% of tryptophan labelled amount in Amino Acid Compound Injection.For example, for amino acid (15) double peptide (2) injections, wherein tryptophan labelled amount are 0.95g/500ml, are used to make standard curve or recurrence side at this time In 3 reference substance solutions of journey the concentration range of 5HTP can be respectively 0.2-0.8 μ g/ml, 1.6-2.4 μ g/ml, 8-10 μ g/ml, for example, the concentration of 5HTP can be about 0.5 μ g/ml, about 2.0 μ g/ respectively in 3 reference substance solutions Ml, about 9.0 μ g/ml.The method of the present invention, the range of linearity are more than the 0.1-0.4% of tryptophan labelled amount.
Preferably, 3-7 are prepared, further preferred 3-5 is a, the L- kynurenin reference substances of more preferable 3 various concentrations Solution.Those skilled in the art have L- in multiple reference substance solutions of the ability selection for making standard curve or regression equation The concentration of kynurenin.Preferably, Cmin should be less than 0.1% of tryptophan labelled amount in Amino Acid Compound Injection, most Big concentration should be higher than that 0.4% of tryptophan labelled amount in Amino Acid Compound Injection.For example, for amino acid (15) double peptides (2) injection, wherein tryptophan labelled amount are 0.95g/500ml, are used to make standard curve at this time or 3 of regression equation right Concentration range according to L- kynurenins in product solution can be 0.2-0.8 μ g/ml, 1.6-2.4 μ g/ml, 8-10 μ g/ml respectively, For example, the concentration of L- kynurenins can be about 0.5 μ g/ml, about 2.0 μ g/ml, about 9.0 μ g/ respectively in 3 reference substance solutions ml.The method of the present invention, the range of linearity are more than the 0.1-0.4% of tryptophan labelled amount.
Preferably, the percent by volume that test solution accounts for contrast solution in contrast solution is 1%, i.e., by test solution 100 times are diluted with solvent.If detecting other chromatographic peaks in test solution 280nm wavelength chromatograms, single peak area must not surpass Cross tryptophan peak area in contrast solution 0.5 times, total peak area must not exceed 5 times of tryptophan peak area in contrast solution.
Preferably, chromatographic condition is:Using trifluoroacetic acid-hyptafluorobutyric acid ion pair chromatography;Chromatographic column is reverse phase C18 colors Compose column, preferably specification be 4.6mm × 250mm, 3 μm, more preferable reverse phase C18AQ chromatographic columns;Detector is UV detector.
Preferably, mobile phase A is -0.3% trifluoroacetic acid of 5.0mmol/L hyptafluorobutyric acids-water, and Mobile phase B is acetonitrile;It is preferred that Ground, using gradient elution, elution program see the table below 1;Preferably, flow velocity 0.5-1.0ml/min, further preferred 0.7- 0.9ml/min, more preferable 0.8ml/min.Preferably, column temperature is 35-45 DEG C, more preferable 40 DEG C.
1 gradient elution program of table
The present invention passes through numerous studies, it is determined that 5HTP and L- kynurenins is in Amino Acid Compound Injections Pointer impurity, by being detected and controlling energy to 5HTP in Amino Acid Compound Injection and L- kynurenins Enough detect and control the related substance in Amino Acid Compound Injection.In particular, the present invention by trifluoroacetic acid-hyptafluorobutyric acid from Son optimizes the various amino acid contained in amino acid injection and the separation in relation to substance and baseline stability to chromatographic process Property, improve detection sensitivity.By methodology validation, it is found that the method for the present invention is sensitive, accurate, reproducibility is preferable, it can Meet the requirement of the related substance control of Amino Acid Compound Injection.
Description of the drawings
5HTP reference substance solution chromatogram under Fig. 1 280nm wavelength
L- kynurenins reference substance solution chromatogram under Fig. 2 365nm wavelength
Test solution chromatogram under Fig. 3 280nm wavelength
Fig. 4 5HTP canonical plottings
Fig. 5 kynurenin canonical plottings
Fig. 6 280nm wavelength lower open mouths stir 1 hour after test solution chromatogram
Specific implementation mode
Present invention will be further explained below with reference to specific examples.It should be understood that these embodiments are merely to illustrate the present invention Rather than it limits the scope of the invention.Furthermore, it is to be understood that after having read recorded content of the invention, this field skill Art personnel can make various changes or modifications the present invention, and such equivalent forms equally fall within limited range of the present invention.
Detection in relation to substance in 1 Amino Acid Compound Injection of embodiment
1. instrument
3000 type high performance liquid chromatographs of Thermo dionex UltiMate (on-line degassing machine, double ternary gradient pumps, DIONEX UltiMate 3000Diode Array Detector, DIONEX UltiMate 3000Autosampler, 7.2 chromatographic work station of DIONEX UltiMate 3000Column Compartment, Chromeleon) (ThermoFisher, the U.S.);Balance (XP205, METTLER TOLEDO companies, Switzerland);Milli-Q Superpure water machines (Integral 10, Merck Millipore companies, Germany);Water phase syringe filter (polyether sulfone, lot number:9G020320, on The general scientific instrument Co., Ltd in Hai'an, China).
2. reagent
Acetonitrile (Merck Chemical Engineering Technology (Shanghai) Co., Ltd., HPLC purity 99.9%, lot number:1312001YT);Trifluoro second Acid (lark prestige Science and Technology Ltd. of Beijing, 99%, lot number:L490O140);Hyptafluorobutyric acid (the limited public affairs of Beijing enlightening equine skill Department, 99.5%, lot number:7281190);Hydrochloric acid:Beijing Chemical Plant, lot number 20140910, content w/%:38.0;Water is ultra-pure water (being more than 18.2M Ω cm).
3. reference substance
L- kynurenins (Sigma, HPLC purity 98%, lot number:BCBP8307V), 5- hydroxyls-L-Trp (Aldrich, HPLC purity 98%, lot number:BCBP2662V).
4. reagent
Amino acid (15) double peptides (2) injection (lot number:14121601, Double-Crane Pharmaceutical Co., Ltd), tryptophan labelled amount is 0.95g/500ml。
5. the detection in relation to substance in Amino Acid Compound Injection
Amino Acid Compound Injection is taken to be directly used as test solution.Precision measures test solution 1ml and is placed in 100ml amounts In bottle, it is diluted to scale with 0.1mol/L aqueous hydrochloric acid solutions, shakes up, is used as contrast solution.Precision weighs 5HTP, It is respectively 0.5105 μ g/ml, 2.002 μ g/ml, 9.544 μ to be configured to 5HTP concentration with 0.1mol/L aqueous hydrochloric acid solutions The 5HTP reference substance solution of g/ml;Precision weighs L- kynurenins, and L- is configured to 0.1mol/L aqueous hydrochloric acid solutions Kynurenin concentration is respectively the L- kynurenin reference substance solutions of 0.5285 μ g/ml, 2.016 μ g/ml, 9.304 μ g/ml.
Using Capcell PAK C18AQ S3 (4.6mm × 250mm, 3 μm) chromatographic column;Mobile phase A:5.0mmol/L seven - 0.3% trifluoroacetic acid of fluorine butyric acid-water, Mobile phase B:Acetonitrile, gradient elution, elution program see the table below 2;Flow velocity 0.8ml/min; 40 DEG C of column temperature;Detection wavelength:280nm and 365nm;In 280nm wavelength chromatograms, number of theoretical plate is based on 5HTP peak Calculate should be not less than 10000,5HTP, L- kynurenins and adjacent chromatographic peak separating degree>1.5.
2 gradient elution program of table
Precision measures test solution, contrast solution and each 10 μ l of two kinds of reference substance solutions, is injected separately into liquid chromatograph, Record the chromatogram and 365nm of test solution, contrast solution and 5HTP reference substance solution under 280nm wavelength The chromatogram of test solution and L- kynurenin reference substance solutions under wavelength.A concentration of 2.0 μ g/ml wherein under 280nm wavelength 5HTP reference substance solution chromatogram, the L- kynurenin reference substances of a concentration of 2.0 μ g/ml under 365nm wavelength The chromatogram of test solution under the chromatogram and 280nm wavelength of solution, see attached drawing 1-3.
It is respectively the 5HTP reference substance solution of 0.5105 μ g/ml, 2.002 μ g/ml, 9.544 μ g/ml with concentration 5HTP peak area is ordinate in 280nm wavelength chromatograms, with a concentration of abscissa of 5HTP, makes mark Directrix curve (see attached drawing 4), by calibration curve method with the peak area of 5HTP in test solution 280nm wavelength chromatograms The 5HTP amount contained in test solution is determined according to the standard curve.The lot number detected in the present embodiment is It is not detected 5HTP peak in 14121601 amino acid (15) double peptides (2) injection, i.e. 5HTP Amount is no more than 0.2% of tryptophan labelled amount in Amino Acid Compound Injection.
It is respectively the L- kynurenin reference substance solutions of 0.5285 μ g/ml, 2.016 μ g/ml, 9.304 μ g/ml with concentration L- kynurenin peak areas are ordinate in 365nm wavelength chromatograms, and with a concentration of abscissa of L- kynurenins, it is bent to make standard Line (see attached drawing 5), by calibration curve method with the peak area of L- kynurenins in test solution 365nm wavelength chromatograms according to this Standard curve determines the L- kynurenin amounts contained in test solution.The lot number that is detected in the present embodiment is 14121601 to answer L- kynurenins peak is not detected in square amino acid (15) double peptides (2) injection, i.e. the amount of L- kynurenins is no more than compound amino The 0.2% of tryptophan labelled amount in acid injection.
Other chromatographic peaks detected in test solution 280nm wavelength chromatograms, it is molten that single peak area is no more than control 0.5 times of tryptophan peak area in liquid, total peak area are no more than 5 times of tryptophan peak area in contrast solution.
The Amino Acid Compound Injection of above-mentioned same lot number is placed in room temperature opening, it is unstable because fully investigating oxidation Property, it sets and stirs 1h on magnetic stirring apparatus, the related substance wherein contained is detected according to above-mentioned same method, find it Test solution detects 5HTP peak (see Fig. 6) at a wavelength of 280 nm, and it is a concentration of to calculate its according to calibration curve method 1.078μg/ml;L- kynurenins are detected under 365nm wavelength, its a concentration of 0.5907 μ g/ml is calculated according to calibration curve method.
2 methodology validation of embodiment
Reference《Chinese Pharmacopoeia》Four annex of version in 2015 carry out methodological study to the detection method of the present invention.Wherein, Used-amino acid (15) double peptides (2) injection (lot number:14121601,14121701,14121801, from double crane medicines Industry)
1. specificity is tested
Blank solvent (0.1mol/L aqueous hydrochloric acid solutions), 5HTP reference substance solution (a concentration of 40.72 are taken respectively μ g/ml), L- kynurenins reference substance solution (a concentration of 60.80 μ g/ml), test solution, test solution:5- hydroxyl colors Propylhomoserin positions solution (a concentration of 400 μ g/ml):It is 1 that L- kynurenins, which position solution (a concentration of 400 μ g/ml),:1:1 mixing Solution injects liquid chromatograph, and chromatographic condition records the chromatogram under 280nm wavelength with embodiment 1, finds blank solvent and confession Other amino acid in test sample solution are noiseless to the measurement of 5-HTP and L- kynurenins, show that the present invention's is special Attribute is good.
2. system suitability
Prepare containing 5HTP, L- kynurenin concentration be respectively 3.802 μ g/ml, 3.722 μ g/ml reference substance Solution, injects liquid chromatograph, and chromatographic condition records the chromatogram under 280nm, 365nm wavelength, 5- hydroxyl colors with embodiment 1 The theoretical cam curve of propylhomoserin is that the theoretical cam curve of 456909, L- kynurenins is 323966, and the separating degree of the two is 8.52.
3. repeatability is investigated
6 parts of parallel preparation is respectively 3.802,3.722 μ g/ml containing 5HTP, L- kynurenin concentration, contains 20% The mark-on test solution of test solution is injected separately into liquid chromatograph, and chromatographic condition is the same as embodiment 1,5HTP (under 280nm wavelength), L- kynurenins (under 365nm wavelength) peak area RSD are respectively 0.30%, 1.89%.
4. quantitative limit
Prepare containing 5HTP, L- kynurenin concentration be respectively 0.8144,1.216mg/ml quantitative limit solution, Liquid chromatograph is constantly diluted and injects, chromatographic condition is with embodiment 1, until signal-to-noise ratio S/N >=10.5HTP The quantitative limit of (under 280nm wavelength), L- kynurenins (under 365nm wavelength) is respectively 0.1629 μ g/ml, 0.2432 μ g/ml.
5. detection limit
Prepare containing 5HTP, L- kynurenin concentration be respectively 0.8144,1.216mg/ml quantitative limit solution, Liquid chromatograph is constantly diluted and injects, chromatographic condition is with embodiment 1, until signal-to-noise ratio S/N >=3.5HTP The detection limit of (under 280nm wavelength), L- kynurenins (under 365nm wavelength) is respectively 0.08144 μ g/ml, 0.1216 μ g/ml.
6. precision is investigated
Take contrast solution (test solution 0.1mol/L aqueous hydrochloric acid solutions dilute 100 times) and containing 5HTP, L- kynurenin concentration is respectively the reference substance solution injection liquid chromatograph of 3.802,3.722 μ g/ml, respectively repeatedly sample introduction 6 Secondary, chromatographic condition is with embodiment 1,5HTP (under 280nm wavelength), L- kynurenins (365nm waves in reference substance solution Under length) peak area RSD is respectively 0.10%, 0.33%, and tryptophan (under 280nm wavelength) peak area RSD is in contrast solution 0.15%.
7. linear test
Prepare concentration containing 5HTP be respectively 814.4,407.2,203.6,40.72,8.144,4.072, 1.629,0.8144,0.3258,0.1629 μ g/ml, L- kynurenin concentration be respectively 1216,608.0,304.0,60.80, 12.16, the control series solution of 6.080,2.432,1.216,0.4864,0.2432 μ g/ml injects liquid chromatograph, chromatography Condition is with embodiment 1, and the linear relationship of 5HTP concentration and peak area is good, regression equation:Y=0.2858X- 0.0011, correlation coefficient r=1.0000, the method range of linearity:0.1629~814.4 μ g/ml;L- kynurenins concentration and peak face Long-pending linear relationship is good, regression equation:Y=0.2014X-0.2513, correlation coefficient r=0.9999, the method range of linearity: 0.2432~1216 μ g/ml.
8. test solution stability
Take be placed at room temperature for 0 hour, 3 hours, 7 hours, 14 hours, 16 hours, 20 hours, 21 hours, 24 hours for examination Product solution and concentration containing 5HTP are respectively the reference substance solution of 0.5105,2.002,9.544 μ g/ml, the urine of dog containing L- Propylhomoserin concentration is respectively the reference substance solution of 0.5285,2.2016,9.304 μ g/ml, is injected separately into liquid chromatograph, chromatostrip Part measures the peak area of 5-OH-Trp and L-KY in test sample sample with embodiment 1.In the test sample placed in 24 hours not 5-OH-Trp and L-KY is detected, Amino Acid Compound Injection has good stability under room temperature.
9. accuracy
Precision measures the test sample (lot number of 2.0mL:14121701) it 9 parts, is respectively placed in the volumetric flask of 10mL, essence is added The close reference substance about 1.0 for measuring (a concentration of 19.92,19.82 μ g/ml of 5HTP, L- kynurenins), 2.0,4.0mL Each 3 parts, scale is diluted to 0.1mol/L HCl, be made mass concentration be about 1.90 μ g/ml, 3.80 μ g/ml, 7.60 μ g/ml Solution be injected separately into liquid chromatograph as accuracy determination solution, chromatographic condition with embodiment 1,5HTP Average recovery rate is 98.86%, RSD=0.78% (n=9), and the average recovery rate of L- kynurenins is 104.8%, RSD= 1.78% (n=9).
10. serviceability test
Prepare containing 5HTP, L- kynurenin concentration be respectively 3.802,3.722 μ g/ml reference substance solution, It is 14121701 test sample to take lot number, and filtration is injected separately into liquid chromatograph, chromatographic condition investigates flow velocity ± 0.1ml/ respectively Min, under the conditions of column temperature ± 5 DEG C, 5HTP, the influence of L- kynurenin peak areas and test sample are molten in reference substance solution The influence of 5HTP, L- kynurenin peak areas in liquid.
The results show that (flow velocity ± 0.1ml/min, column temperature ± 5 DEG C) change testing conditions in a certain range, to 5- Hydroxytryptophan, the determination influences of L- kynurenins are little.
More than, embodiments of the present invention are illustrated.But the present invention is not limited to the above embodiments.It is all Within the spirit and principles in the present invention, any modification, equivalent substitution, improvement and etc. done should be included in the guarantor of the present invention Within the scope of shield.

Claims (10)

1. the detection method in relation to substance in a kind of Amino Acid Compound Injection, which is characterized in that this method comprises the following steps:
(1) preparation of test solution and reference substance solution:
Amino Acid Compound Injection is taken to be directly used as test solution;
Prepare the L- kynurenins of the 5HTP reference substance solution and at least three various concentration of at least three various concentration Reference substance solution;
(2) it takes the 5HTP reference substance solution of various concentration to inject high performance liquid chromatograph, records under 280nm wavelength not With the chromatogram of the 5HTP reference substance solution of concentration, with a concentration of abscissa of 5HTP, with the concentration Corresponding peak area is ordinate, makes standard curve or regression equation;Take the L- kynurenin reference substances of various concentration molten Liquid injects high performance liquid chromatograph, records the chromatogram of the L- kynurenin reference substance solutions of various concentration under 365nm wavelength, with A concentration of abscissa of L- kynurenins makes standard curve or recurrence side using the peak area corresponding to the concentration as ordinate Journey;
(3) take test solution inject high performance liquid chromatograph, record 280nm wavelength under and 365nm wavelength under test solution Chromatogram, by calibration curve method, with the peak area of 5HTP in test solution 280nm wavelength chromatograms according to mark The amount of 5HTP, must not exceed color in Amino Acid Compound Injection in directrix curve or regression equation calculation test solution The 0.2% of propylhomoserin labelled amount, with the peak area of L- kynurenins in test solution 365nm wavelength chromatograms according to standard curve Or in regression equation calculation test solution L- kynurenins amount, must not exceed in Amino Acid Compound Injection tryptophan and indicate The 0.2% of amount;
Wherein, contain tryptophan in the Amino Acid Compound Injection.
It is preferred that the Amino Acid Compound Injection is amino acid (15) double peptides (2) injection, Amino Acid Compound Injection (18AA) (specification includes 5% and 12%), Amino Acid Compound Injection (18AA-I), Amino Acid Compound Injection (18AA-II) (specification includes 5%, 8.5%, 11.4%), Amino Acid Compound Injection (18AA-III), Amino Acid Compound Injection (18AA- V), Amino Acid Compound Injection (18AA- VII), Amino Acid Compound Injection (20AA), Amino Acid Compound Injection (15AA), multiple Square amino acid injection (14AA), Amino Acid Compound Injection (17AA).
It is preferred that the Amino Acid Compound Injection is amino acid (15) double peptides (2) injection.
2. according to the method described in claim 1, it is characterized in that, in step (1), further prepares and contain test solution Contrast solution;In step (2), contrast solution is further taken to inject high performance liquid chromatograph, records and compareed under 280nm wavelength The chromatogram of solution;In step (3), by Self-control method, if detecting its allochromatic colour in test solution 280nm wavelength chromatograms Spectral peak, single peak area is by the way that compared with tryptophan peak area in contrast solution, content must not exceed Amino Acid Compound Injection The 0.5% of middle tryptophan labelled amount, total peak area is by the way that compared with tryptophan peak area in contrast solution, content must not exceed multiple The 5% of tryptophan labelled amount in square amino acid injection.
3. method according to claim 1 or 2, which is characterized in that the solvent for preparing reference substance solution is that dilute hydrochloric acid is water-soluble Liquid, the aqueous hydrochloric acid solution of more preferable a concentration of 0.1mol/L.
4. method according to any one of claim 1-3, which is characterized in that the solvent of contrast solution is that dilute hydrochloric acid is water-soluble Liquid, the aqueous hydrochloric acid solution of more preferable a concentration of 0.1mol/L.
5. according to the described method of any one of claim 1-4, which is characterized in that 3-7 are prepared, further preferred 3-5 is a, The 5HTP reference substance solution of more preferable 3 various concentrations.
It is preferred that the Cmin of 5HTP is answered in multiple reference substance solutions for making standard curve or regression equation Less than 0.1% of tryptophan labelled amount in Amino Acid Compound Injection, maximum concentration should be higher than that color in Amino Acid Compound Injection The 0.4% of propylhomoserin labelled amount.
It is preferred that Amino Acid Compound Injection is amino acid (15) double peptides (2) injection, tryptophan labelled amount is 0.95g/ 500ml, the concentration range of 5HTP is respectively in 3 reference substance solutions for making standard curve or regression equation 0.2-0.8 μ g/ml, 1.6-2.4 μ g/ml, 8-10 μ g/ml, it is further preferred that in 3 reference substance solutions 5HTP concentration It is about 0.5 μ g/ml, about 2.0 μ g/ml, about 9.0 μ g/ml respectively.
6. method according to any one of claims 1-5, which is characterized in that 3-7 are prepared, further preferred 3-5 is a, The L- kynurenin reference substance solutions of more preferable 3 various concentrations.
It is preferred that in multiple reference substance solutions for making standard curve or regression equation the Cmin of L- kynurenins answer it is low The 0.1% of tryptophan labelled amount in Amino Acid Compound Injection, maximum concentration should be higher than that color ammonia in Amino Acid Compound Injection The 0.4% of sour labelled amount.
It is preferred that Amino Acid Compound Injection is amino acid (15) double peptides (2) injection, tryptophan labelled amount is 0.95g/ 500ml, the concentration range of L- kynurenins is respectively in 3 reference substance solutions for making standard curve or regression equation 0.2-0.8 μ g/ml, 1.6-2.4 μ g/ml, 8-10 μ g/ml, it is further preferred that the concentration of L- kynurenins is divided in 3 reference substance solutions It is not about 0.5 μ g/ml, about 2.0 μ g/ml, about 9.0 μ g/ml.
7. according to the method described in any one of claim 1-6, which is characterized in that test solution accounts for control in contrast solution The percent by volume of solution is 1%, i.e., test solution solvent is diluted 100 times;Test solution 280nm wavelength chromatograms If other chromatographic peaks are detected in, single peak area must not exceed 0.5 times of tryptophan peak area in contrast solution, and total peak area is not Obtain 5 times more than tryptophan peak area in contrast solution.
8. according to the described method of any one of claim 1-7, which is characterized in that use trifluoroacetic acid-hyptafluorobutyric acid ion To chromatography.
It is preferred that chromatographic column be reverse phase C18 chromatographic columns, further preferred specification be 4.6mm × 250mm, 3 μm, more preferable reverse phase C18AQ chromatographic columns.
It is preferred that detector is UV detector.
9. according to the method described in any one of claim 1-8, which is characterized in that mobile phase A is seven fluorine fourths of 5.0mmol/L Sour -0.3% trifluoroacetic acid-water, Mobile phase B is acetonitrile;Preferably, using gradient elution, elution program see the table below:
10. according to the method described in any one of claim 1-9, which is characterized in that flow velocity 0.5-1.0ml/min, preferably 0.7-0.9ml/min, more preferable 0.8ml/min.
It is preferred that column temperature is 35-45 DEG C, more preferable 40 DEG C.
CN201810457668.7A 2018-05-14 2018-05-14 Method for detecting related substances in compound amino acid injection Active CN108663448B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810457668.7A CN108663448B (en) 2018-05-14 2018-05-14 Method for detecting related substances in compound amino acid injection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810457668.7A CN108663448B (en) 2018-05-14 2018-05-14 Method for detecting related substances in compound amino acid injection

Publications (2)

Publication Number Publication Date
CN108663448A true CN108663448A (en) 2018-10-16
CN108663448B CN108663448B (en) 2021-07-13

Family

ID=63778387

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810457668.7A Active CN108663448B (en) 2018-05-14 2018-05-14 Method for detecting related substances in compound amino acid injection

Country Status (1)

Country Link
CN (1) CN108663448B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109406684A (en) * 2018-12-26 2019-03-01 北京哈三联科技有限责任公司 A kind of detection method measuring impurity B in the Amino Acid Compound Injection containing tryptophan, C, D content
CN112697934A (en) * 2020-12-10 2021-04-23 武汉久安药业有限公司 Method for detecting content of pyroglutamic acid in compound amino acid injection
CN112858556A (en) * 2021-01-14 2021-05-28 费森尤斯卡比华瑞制药有限公司 Method for detecting tryptophan impurities in compound amino acid solution
CN112946099A (en) * 2021-01-25 2021-06-11 石家庄四药有限公司 Method for detecting related substances in amino acid glucose injection

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101776662A (en) * 2010-01-15 2010-07-14 中南大学湘雅二医院 Method for simultaneously determining tryptophan, kynurenine and kynurenicacid by using high performance liquid chromatography-fluorescence method
CN104391053A (en) * 2014-10-30 2015-03-04 广东新峰药业股份有限公司 PR-HPLC (phase reversing-high performance liquid chromatography) determination method for simultaneously determining contents of five amino acids in earthworm injection
US20160116461A1 (en) * 2006-10-13 2016-04-28 Metabolon, Inc. Biomarkers Related To Metabolic Age and Methods Using The Same
CN107102152A (en) * 2017-05-17 2017-08-29 中国医学科学院基础医学研究所 The protein marker of urine myocardial infarction and its purposes in diagnosis and prognosis
CN107907603A (en) * 2017-10-31 2018-04-13 华仁药业股份有限公司 A kind of measure assay method of the amino acids parenteral solution tryptophan in relation to material

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160116461A1 (en) * 2006-10-13 2016-04-28 Metabolon, Inc. Biomarkers Related To Metabolic Age and Methods Using The Same
CN101776662A (en) * 2010-01-15 2010-07-14 中南大学湘雅二医院 Method for simultaneously determining tryptophan, kynurenine and kynurenicacid by using high performance liquid chromatography-fluorescence method
CN104391053A (en) * 2014-10-30 2015-03-04 广东新峰药业股份有限公司 PR-HPLC (phase reversing-high performance liquid chromatography) determination method for simultaneously determining contents of five amino acids in earthworm injection
CN107102152A (en) * 2017-05-17 2017-08-29 中国医学科学院基础医学研究所 The protein marker of urine myocardial infarction and its purposes in diagnosis and prognosis
CN107907603A (en) * 2017-10-31 2018-04-13 华仁药业股份有限公司 A kind of measure assay method of the amino acids parenteral solution tryptophan in relation to material

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LYSIANE BOULET 等: "Simultaneous determination of tryptophan and 8 metabolites in human plasma by liquid chromatography/tandem mass spectrometry", 《JOURNAL OF CHROMATOGRAPHY B》 *
NOBLE KUMAR TALARI 等: "Altered tryptophan metabolism in human meningioma", 《JOURNAL OF NEURO-ONCOLOGY VOLUME》 *
王玉红 等: "高效液相色谱-蒸发光散射检测法直接检测20种未衍生基本氨基酸", 《色谱》 *
赵建幸 等: "高效液相色谱-紫外、荧光双检测器同时测定人尿中犬尿氨酸和犬尿喹啉酸", 《检验医学》 *
魏永锋 等: "比值导数荧光光谱法同时测定色氨酸和5-羟基色氨酸", 《分析试验室》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109406684A (en) * 2018-12-26 2019-03-01 北京哈三联科技有限责任公司 A kind of detection method measuring impurity B in the Amino Acid Compound Injection containing tryptophan, C, D content
CN109406684B (en) * 2018-12-26 2021-11-12 北京哈三联科技有限责任公司 Detection method for determining content of impurity B, C, D in tryptophan
CN112697934A (en) * 2020-12-10 2021-04-23 武汉久安药业有限公司 Method for detecting content of pyroglutamic acid in compound amino acid injection
CN112858556A (en) * 2021-01-14 2021-05-28 费森尤斯卡比华瑞制药有限公司 Method for detecting tryptophan impurities in compound amino acid solution
CN112946099A (en) * 2021-01-25 2021-06-11 石家庄四药有限公司 Method for detecting related substances in amino acid glucose injection

Also Published As

Publication number Publication date
CN108663448B (en) 2021-07-13

Similar Documents

Publication Publication Date Title
CN108663448A (en) Detection method in relation to substance in a kind of Amino Acid Compound Injection
CN107907603B (en) Method for measuring tryptophan related substances in amino acid injection
CN106940355B (en) A kind of brufen, the detection method of its sodium salt and its preparation in relation to substance
CN104597171A (en) High performance liquid chromatography analysis method of acarbose and its preparation
CN112946099B (en) Method for detecting related substances in amino acid glucose injection
CN106706789A (en) Method for detecting related substances in drotaverine hydrochloride injection by high performance liquid chromatography
CN108828085A (en) A kind of total amino acid quantitative detecting method of transfer factor capsule
CN109100456B (en) Method for simultaneously determining content of 3 fat-soluble vitamins in multivitamin injection
CN107991415B (en) Method for simultaneously separating and measuring pyroglutamic acid and methionine sulfoxide impurities in compound amino acid injection 18AA by liquid chromatography
CN110514759A (en) The detection method of azido compound in a kind of candesartan Cilexetil
CN116087392A (en) Detection method for detecting finger print and content measurement of hovenia dulcis thunb particles
CN102841169B (en) Method for measuring calcium levofolinate-related substances by using high performance liquid chromatography gradient method
CN115356420A (en) Pudilan anti-inflammatory tablet quality evaluation method based on one-test-multiple evaluation
CN108414636A (en) A kind of detection method of the cinnarizine in relation to substance
CN108037221B (en) Method for simultaneously separating and determining methionine sulfoxide and methionine sulfone impurities in compound amino acid injection 18AA by liquid chromatography
CN113588817A (en) Method for simultaneously determining content of atropine sulfate and EDTA-2Na in atropine eye drops
CN107884496B (en) Method for determining content of succinic acid in trelagliptin succinate
CN112697934A (en) Method for detecting content of pyroglutamic acid in compound amino acid injection
CN112305138B (en) Method for simultaneously determining content of lysine and glycine
CN110208397A (en) High performance liquid chromatography that is a kind of while measuring two kinds of drug contents in terramycin Flunixin injection
CN115236255B (en) Method for detecting related substances of loxoprofen sodium
CN111380991B (en) Method for detecting content of degradation impurities in vitamin C medicament
CN114660213B (en) Component content determination method of compound reserpine hydrochlorothiazide tablet
CN115166083B (en) Method for detecting fosfomycin trometamol related substances and application thereof
CN110907548B (en) Method for detecting biapenem and/or related substances

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant